Novabay Pharmaceuticals Inc Precio/Valor contable
¿Qué es el Precio/Valor contable de Novabay Pharmaceuticals Inc?
El Precio/Valor contable de Novabay Pharmaceuticals Inc es 0.98
¿Cuál es la definición de Precio/Valor contable?
El ratio precio-valor contable representa la relación entre el valor de las acciones de una empresa y el valor contable por acción.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Precio/Valor contable de compañías en Sector Health Care en NYSEMKT en comparadas con Novabay Pharmaceuticals Inc
¿Qué hace Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Empresas con precio/valor contable similar a Novabay Pharmaceuticals Inc
- Kubota tiene Precio/Valor contable de 0.98
- China Leasing tiene Precio/Valor contable de 0.98
- Worldwide Healthcare Trust Plc tiene Precio/Valor contable de 0.98
- Jaguar Health Inc tiene Precio/Valor contable de 0.98
- Manulife Floating Rate Senior Loan Fund tiene Precio/Valor contable de 0.98
- Broadstone Net Lease tiene Precio/Valor contable de 0.98
- Novabay Pharmaceuticals Inc tiene Precio/Valor contable de 0.98
- Cinevista tiene Precio/Valor contable de 0.98
- Alpha & Omega Semiconductor Ltd tiene Precio/Valor contable de 0.98
- abrdn Life Sciences Investors tiene Precio/Valor contable de 0.98
- Nile tiene Precio/Valor contable de 0.98
- Bénéteau SA tiene Precio/Valor contable de 0.98
- Green Brick Partners tiene Precio/Valor contable de 0.98